Questions and... Speculations
I just thought of something that would probably answer most of your questions...
Q: Why hasn't Dr. Toleikis assembled a team to begin work on x
Remember way back when Sernova announced multiple collaborations with multiple pharmaceutical companies? That means atleast 2 teams working on different indications. Maybe even more.
Ever thought maybe the reason we don't have answers is because the answers are locked behind NDA's regarding those collaborations? Maybe Dr. Toleikis doesn't need to employ is own research staff because there are other pharma companies doing the work for him. Maybe they are doing year long pre-clinical trials. Who knows, but I'd imagine the NDA's would withold for the duration of their study.
Q: Why did Dr. Toleikis agree to that bot deal??
We will likely never know what happened with the bot deal financing that took place back in february. But I do think they learnt from their mistakes and we should probably move on.
Q: Where is the progress on xxx indication?
Let me again remind you that that information is likely hidden behind NDA's. And of course these NDA's would be quite strict to keep competitors from catching wind of this small publicly traded Canadian company looking to strike a deal.
Q: Where did x person go?
Finally, in regards to the restructuring, I can understand why Dominic was willing to go, we Sernova investors are a tough crowd to please, and communicating with us would be a chore. I look forward to his replacement who may be able to spruce up some of these press releases, and better communicate with investors. And R&D is due for a change in direction, there is no longer the need for researching a device that can sustain the survival of cells. What we need to be researching next is immunosupression. We need to bring on an expert in the field to build his own team and lead that development. Unfortunately, this kind of person doesn't just grow on trees. But I do think the vacating of these positions presents an excellent opportunity to upgrade the company and bring on new talent.